 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...4647484950515253545556...235236» |
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
Journal, Real-world evidence, Real-world: Real-world tolerance and outcomes of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer-Does dose intensity matter? (Pubmed Central) - May 22, 2023
In a real-world setting, patients who received CAPOX had similar OS rates when compared to those receiving FOLFOX in the adjuvant setting in spite of lower RDI. In the high-risk population, CAPOX appears to demonstrate a superior 5-year DFS over FOLFOX.
- ||| zolbetuximab (IMAB362) / Astellas
P3 data, Journal, Metastases: Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. (Pubmed Central) - May 22, 2023
P3
Targeting CLDN18.2 with zolbetuximab significantly prolonged progression-free survival and overall survival when combined with mFOLFOX6 versus placebo plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Zolbetuximab plus mFOLFOX6 might represent a new first-line treatment in these patients.
- | Retrospective data, Journal, BRCA Biomarker: Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan. (Pubmed Central) - May 22, 2023
Zolbetuximab plus mFOLFOX6 might represent a new first-line treatment in these patients. ACC clearly harbors different genomics compared with PDAC, possibly accounting for differences in treatment efficacy.
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Clinical, P2b data, Journal, Metastases: Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial. (Pubmed Central) - May 22, 2023
P2
The combination of nal-IRI plus FU/LV could be considered as a second-line treatment option for patients with previously treated advanced BTC. clinicaltrials.gov Identifier: NCT03524508.
- | New P2 trial, Metastases: ISANOX: Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer (clinicaltrials.gov) - May 22, 2023
P2, N=70, Active, not recruiting, Sponsor: Salah Aza
- | Enrollment open, Metastases: Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer (clinicaltrials.gov) - May 22, 2023
P=N/A, N=446, Recruiting, Sponsor: Nanfang Hospital of Southern Medical University
clinicaltrials.gov Identifier: NCT03524508. Not yet recruiting --> Recruiting
- |||| Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment open: ERASE-CRC: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (clinicaltrials.gov) - May 22, 2023
P2, N=300, Recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (clinicaltrials.gov) - May 22, 2023
P1, N=2, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=40 --> 2 | Trial completion date: Feb 2026 --> Jun 2027 | Trial primary completion date: Feb 2023 --> Jun 2025
- Associations of Inflammatory Biomarkers with Survival Among Patients with Stage III Colon Cancer (CALGB/SWOG 80702). () - May 21, 2023 - Abstract #SWOGSpring2023SWOG_Spring_354;
P2
Among the first 30 evaluable patients enrolled to each arm, 17 patients in arm 1 (57%) and 10 patients in arm 2 (33%) had undergone R0 resection, leading to closure of arm 2 but continuation to full enrollment in arm 1. The 18-month OS rate of evaluable patients was 66.7% (95% CI, 56.1%-79.4%) in arm 1 and 47.3% (95% CI 35.8%-62.5%) in arm 2.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
ARID1A mutations induce an EGFR-like signature and confer intrinsic and acquired resistance to cetuximab treatment in colon cancer () - May 21, 2023 - Abstract #SWOGSpring2023SWOG_Spring_353;
P2
Among the first 30 evaluable patients enrolled to each arm, 17 patients in arm 1 (57%) and 10 patients in arm 2 (33%) had undergone R0 resection, leading to closure of arm 2 but continuation to full enrollment in arm 1. The 18-month OS rate of evaluable patients was 66.7% (95% CI, 56.1%-79.4%) in arm 1 and 47.3% (95% CI 35.8%-62.5%) in arm 2.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Acquired Genomic Alterations on First Line Chemotherapy with Cetuximab/Bevacizumab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of CALGB/SWOG-80405 Trial () - May 21, 2023 - Abstract #SWOGSpring2023SWOG_Spring_352;
P2
Among the first 30 evaluable patients enrolled to each arm, 17 patients in arm 1 (57%) and 10 patients in arm 2 (33%) had undergone R0 resection, leading to closure of arm 2 but continuation to full enrollment in arm 1. The 18-month OS rate of evaluable patients was 66.7% (95% CI, 56.1%-79.4%) in arm 1 and 47.3% (95% CI 35.8%-62.5%) in arm 2.
- irinotecan / Generic mfg.
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. () - May 21, 2023 - Abstract #SWOGSpring2023SWOG_Spring_351;
P2
Among the first 30 evaluable patients enrolled to each arm, 17 patients in arm 1 (57%) and 10 patients in arm 2 (33%) had undergone R0 resection, leading to closure of arm 2 but continuation to full enrollment in arm 1. The 18-month OS rate of evaluable patients was 66.7% (95% CI, 56.1%-79.4%) in arm 1 and 47.3% (95% CI 35.8%-62.5%) in arm 2.
- ||| @AmericanCancer list of drugs in short supply: carboplatin fludarabine dacarbazine amifostine azacitidine capecitabine cisplatin cytarabine dexamethasone hydrocortisone leucovorin Lu 177 methotrexate pentostatin streptozocin This is a crisis. #WeNeedChemoDrugs (Twitter) - May 21, 2023
- | Journal, Metastases: Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study. (Pubmed Central) - May 20, 2023
The 18-month OS rate of evaluable patients was 66.7% (95% CI, 56.1%-79.4%) in arm 1 and 47.3% (95% CI 35.8%-62.5%) in arm 2. The survival advantage of second-line CTx, was observed in patients with scores of 0 and 1 but not in those with score 2.
- | vanucizumab (RG7221) / Roche
Journal: Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial. (Pubmed Central) - May 19, 2023
P2
These data suggest that Ang-2 may be both a prognostic biomarker in mCRC and a predictive biomarker for vanucizumab in KRAS wild-type mCRC. Thus, this evidence can potentially support the establishment of more tailored treatment approaches for patients with mCRC.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
@NVijayvergiaMD Don't know about smarter .... you have it right on ... FOLFOX , although less preferable than observation and IO if needed at progression ... Perhaps a good place to consider MRD assesment ... (Twitter) - May 19, 2023
- || certepetide (LSTA1) / Lisata Therap
Trial completion date, Trial primary completion date: BOLSTER: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 19, 2023
P2a, N=120, Recruiting, Sponsor: Lisata Therapeutics, Inc.
Thus, this evidence can potentially support the establishment of more tailored treatment approaches for patients with mCRC. Trial completion date: May 2026 --> Dec 2025 | Trial primary completion date: May 2026 --> Dec 2025
- || Trial completion date, Trial primary completion date, Metastases: GEMINI-Gastric: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - May 19, 2023
P2, N=80, Recruiting, Sponsor: AstraZeneca
Trial completion date: May 2026 --> Dec 2025 | Trial primary completion date: May 2026 --> Dec 2025 Trial completion date: Mar 2025 --> Feb 2026 | Trial primary completion date: Jun 2024 --> Aug 2025
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., zoledronic acid / Generic mfg.
New P3 trial: HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC (clinicaltrials.gov) - May 19, 2023
P3, N=264, Recruiting, Sponsor: Sun Yat-sen University
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Trial completion date, Trial primary completion date, IO biomarker: Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma (clinicaltrials.gov) - May 19, 2023
P2, N=40, Active, not recruiting, Sponsor: University of Kansas Medical Center
Trial completion date: Mar 2025 --> Feb 2026 | Trial primary completion date: Jun 2024 --> Aug 2025 Recruiting --> Active, not recruiting | Trial completion date: Apr 2023 --> Apr 2025 | Trial primary completion date: Apr 2023 --> Apr 2024
- | Biomarker, Journal: Haematological and nutritional prognostic biomarkers for patients receiving CROSS or FLOT. (Pubmed Central) - May 18, 2023
This demonstrates that a high inflammatory state represented by an NLR ?2, both at baseline and sustained, is prognostic and predictive of response in patients receiving FLOT or CROSS. Baseline hypoalbuminaemia is predictive of poorer outcomes.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
P2 data, Journal, Epigenetic controller, Metastases: Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201. (Pubmed Central) - May 18, 2023
Biweekly cetuximab plus mFOLFOX6 or mFOLFIRI is a useful second-line therapy for mCRC. DNA methylation status warrants further exploration as a predictive biomarker for anti-EGFR efficacy in mCRC.
- || BNT327 / BioNTech
New P2 trial: PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma (clinicaltrials.gov) - May 18, 2023
P2, N=35, Recruiting, Sponsor: Biotheus Inc.
- | Imjudo (tremelimumab) / AstraZeneca, Pfizer, Avastin (bevacizumab) / Roche, Imfinzi (durvalumab) / AstraZeneca
New P2 trial: HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma (clinicaltrials.gov) - May 18, 2023
P2, N=30, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion: Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy (clinicaltrials.gov) - May 18, 2023
P=N/A, N=54, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
DNA methylation status warrants further exploration as a predictive biomarker for anti-EGFR efficacy in mCRC. Active, not recruiting --> Completed
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical: Our phase 2 trial of @viewray 50 Gy/5 fx + @Novocure #TTFields to the entire abdomen for LAPC is finally open for accrual @MiamiCancerInst @BHCancerCare!! ➡️Pts eligible after 4+ months FOLFIRINOX w/o progression ➡️Primary endpoint median PFS https://t.co/DdGqLFi808 (Twitter) - May 17, 2023
- || methotrexate / Generic mfg.
Review, Journal: Methotrexate-Induced Severe Pancytopenia in a Patient with Rheumatoid Arthritis: A Case Report and Review of Literature. (Pubmed Central) - May 17, 2023
Leucovorin, hydration, and urine alkalinization were among the most frequently used treatments. Finally, we summarize the data on the toxicities of low doses of MTX in different diseases.
- | Avastin (bevacizumab) / Roche
New P3 trial: COLLISION RELAPSE Trial (clinicaltrials.gov) - May 17, 2023
P3, N=360, Recruiting, Sponsor: Amsterdam UMC, location VUmc
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
New P3 trial: Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (clinicaltrials.gov) - May 17, 2023
P3, N=408, Not yet recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
- || Review, Journal: Role for Neoadjuvant Systemic Therapy for Potentially Resectable Pancreatic Cancer. (Pubmed Central) - May 16, 2023
FOLFIRINOX is perhaps the preferred regimen, given its proven adjuvant benefit and possibly its superior tumor response rate; still, patient tolerance and thus ability to complete recommended treatment must be carefully considered. This review presents the evidence supporting neoadjuvant chemotherapy for resectable pancreatic cancer, the factors to consider when making such a recommendation, the selection of specific regimens, and our institutional approach using these tools.
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Lynparza (olaparib) / Merck (MSD), AstraZeneca
Clinical: OTOH if patient has responded to FOLFOX then I would like to try Olaparib maintanence along with Cap (Twitter) - May 16, 2023
- |||| Clinical: Frankly if the disease has progressed after Oxaliplatin, then I doubt PARP inhibitors will work. Platinum sensitivity is a good indicator of PARP inhibitors efficacy & Platinum resistant cases are generally excluded from trials of PARPi So I would go for FOLFIRI + Bev (Twitter) - May 16, 2023
- ||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open, Combination therapy, Metastases: A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov) - May 16, 2023
P2, N=60, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
This review presents the evidence supporting neoadjuvant chemotherapy for resectable pancreatic cancer, the factors to consider when making such a recommendation, the selection of specific regimens, and our institutional approach using these tools. Not yet recruiting --> Recruiting
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
FOLFIRI + Bev. I personally have not been impressed with PARPi after progression on platinum. Have had responses if oxali dc due to neuropathy w/o progression (Twitter) - May 15, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Keytruda (pembrolizumab) / Merck (MSD)
Surgery, Circulating tumor DNA, Post-surgery: @aparna1024 @KristenCiombor @GIcancerDoc @doctorC369 @smitha42 @CathyEngMD Stage IIA MSI-H Colon cancer, post-surgery ctDNA (+) What's your preferred tx option? 1) 3 or 6 months CAPOX/FOLFOX 2) Start with Pembro 3) 3 months chemo followed by Pembro if there's a recurrence (Twitter) - May 15, 2023
- | 5-fluorouracil / Generic mfg.
Retrospective data, Journal: Comparison of Neoadjuvant Systemic Chemotherapy Protocols for the Curative-Intent Management of Peritoneal Metastases from Colorectal Cancer, Regarding Morphological Response, Pathological Response, and Long-Term Outcomes: A Retrospective Study. (Pubmed Central) - May 15, 2023
In this retrospective study, a FOLFIRINOX regimen as NACT seemed to result in better long-term outcomes for CRPM patients after complete CRS/HIPEC, although with higher morbidity. Prospective studies are needed, including groups without NACT and those with FOLFIRINOX
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Surgery: Coiling of liver lesions->SCRT to rectum->FOLFOX->SURGERY (LAR + Metastatectomy) (Twitter) - May 14, 2023
- | 5-fluorouracil / Generic mfg.
Journal: Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET). (Pubmed Central) - May 13, 2023
FOLFOX/XELOX chemotherapy is active as the first-line treatment of patients with G3 GEP-NET. The mutational landscape of G3 NET is more similar to well-differentiated NETs than NECs.
- | Journal: Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy. (Pubmed Central) - May 13, 2023
Our results also suggest that the tumor size of 1.0 cm is a better cut off for ypT2. Our study highlights the importance of systemic pathologic examination and the reporting of post-treatment pancreatectomies.
- | cisplatin / Generic mfg., gemcitabine / Generic mfg.
Journal: Multidisciplinary Treatment of Patients with Progressive Biliary Tract Cancer after First-Line Gemcitabine and Cisplatin: A Single-Center Experience. (Pubmed Central) - May 13, 2023
Multidisciplinary discussion is critical for identifying patients with progressive uBTC who might benefit the most from MIT, FOLFIRI, or both. The safety profile was consistent with previous reports.
- || Review, Journal, Metastases: Selecting a TNT Schedule in Locally Advanced Rectal Cancer: Can We Predict Who Actually Benefits? (Pubmed Central) - May 13, 2023
The safety profile was consistent with previous reports. A plethora of potential chemotherapy schedules are available around the radiotherapy component, which include preoperative induction or consolidation with a range of options (FOLFOXIRI, FOLFOX, or CAPEOX,) and a varying duration of 6-18 weeks, prior to long course chemoradiation (LCCRT) or consolidation NACT following short-course preoperative radiation therapy (SCPRT) using 5
- | Journal: Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-institutional validated risk classification. (Pubmed Central) - May 13, 2023
This study developed a clinical risk score based on an international cohort that predicts PRS in patients who underwent surgical resection for PDAC. This risk score will become available on www.evidencio.com and can help clinicians with patient counseling on prognosis.
- | 5-fluorouracil / Generic mfg.
Retrospective data, Journal: Impact of network treatment in patients with resected pancreatic cancer on use and timing of chemotherapy and survival. (Pubmed Central) - May 12, 2023
In this nationwide analysis, network treatment in patients with resected pancreatic cancer was not associated with longer time to chemotherapy, failure to complete adjuvant chemotherapy, and worse survival. Significant variation between pancreatic cancer networks was found for time to chemotherapy.
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Circulating tumor DNA: NRG GI-005 (COBRA) is randomizing patients with stage IIA colon cancer to standard of care vs. ctDNA-guided management (+ signal --> adjuvant with some investigator discretion: FOLFOX up to 12x, CAPOX up to 8x) @NRGgg @SWOG @COLONTOWN1 #crcsm #swogonc https://t.co/MWhY8LVh0z (Twitter) - May 12, 2023
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
SYNCHRONOUS SOLID TUMORS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: EXPERIENCE IN A PUBLIC HEALTHY SYSTEM IN BRAZIL. () - May 12, 2023 - Abstract #EHA2023EHA_2751;
There is no standard approach for synchronous hematological malignancies and solid tumors. Treatment always should be discussed with multidisciplinary team, considering features of the patient's disease and functional status.Case Age Gender Solid Tumor Hematological Malignance Interval (Days) Death Diagnosis Treatment Diagnosis Treatment 1 51 M Calon adenocarcinoma Surgery DLBCL ImunoQT (R-CHOP) 12 No 2 69 F Gastric adenocarcinoma Surgery DLBCL ImunoQT (R-CHOP) 151 Yes 3 57 F Endometrial Neoplasia Surgery Plasmablastic Lymphoma QT (DA- EPOCH) 106 Yes 4 66 1 Colorectar carcinoma in situ Surgery Multiple Myeloma QT (VCD) + RT anti
- methotrexate IV / Generic mfg.
EFFECT OF GLUCARPIDASE RESCUE IN PATIENTS WITH HIGH-DOSE METHOTREXATE INDUCED ACUTE KIDNEY INJURY: A FRENCH PHARMACOVIGILANCE DATABASE STUDY (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1427;
Renal outcome at day 7 seems to be correlated to both baseline eGFR and AKI severity independently of GP rescue. Our data suggest that even GP lowers methotrexate plasmatic levels, it does not seem to improve renal outcome at day 7, thought it has no effect on intracellular methotrexate concentrations.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Journal, Surgery: Intraoperative indocyanine green clearance in liver surgery: a useful tool to promote parenchymal preservation? (Pubmed Central) - May 12, 2023
Therefore, chemotherapy regimen was switched to FOLFIRI/cetuximab (12 cycles)...Postoperative course was uneventful and adjuvant capecitabine was administered (8 cycles)...However, eighteen months following surgery, she developed impairment of hepatic function and portal hypertension. Preoperative ICG administration could be helpful to intraoperatively detect patients that can develop late post hepatectomy impairment of hepatic function, especially following SIRT2 (REF2), and promote parenchymal preservation.
- || Elitek (rasburicase) / Sanofi
Review, Journal: Rescue Therapies for AKI in Onconephrology: Rasburicase and Glucarpidase. (Pubmed Central) - May 11, 2023
Guidelines for using rasburicase and glucarpidase as rescue therapies for TLS and HD MTX toxicity, respectively, are widely used by clinicians intending to mitigate organ toxicity and decrease morbidity and mortality as a consequence of cancer therapy. This review discusses the pathogenesis of TLS and HD MTX-associated toxicity, to understand the mechanism of action of these therapeutic agents and to review the currently available evidence supporting their use.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Diffuse Large B-Cell Lymphoma Pituitary Metastasis (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_964;
She was initiated on methotrexate and leucovorin chemotherapy. This is an unprecedented case of metastatic DLBCL to the leptomeninges, hypothalamus, and pituitary infundibulum confirmed by CSF cytologic analysis that presented in the context of associated panhypopituitarism that manifested initially as SIADH followed by sudden DI.Abbreviations: R-CHOP: Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone